Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results
Hassan R, et al.
Nature Medicine
August 2023
Authors and Affiliates
Raffit Hassan 1, Marcus Butler 2, Roisin E O'Cearbhaill 3, David Y Oh 4, Melissa Johnson 5, Kevin Zikaras 6, Munisha Smalley 6, Michael Ross 6, Janos L Tanyi 7, Azam Ghafoor 8, Nirali N Shah 9, Babak Saboury 10, Liang Cao 11, Alfonso Quintás-Cardama 12, David Hong 13;
1 Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. hassanr@mail.nih.gov.
2 Princess Margaret Cancer Centre, Toronto, ON, Canada.
3 Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
4 Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
5 Sarah Cannon Cancer Center, Nashville, TN, USA.
6 TCR2 Therapeutics, Cambridge, MA, USA.
7 Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, USA.
8 Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
9 Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
10 Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
11 Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
12 TCR2 Therapeutics, Cambridge, MA, USA. alfonso.quintas@tcr2.com.
13 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. dshong@mdanderson.org.